Anti-Human TNFRSF10A Recombinant Antibody (Mapatumumab) (CAT#: TAB-H48)

Recombinant human antibody to Human TNFRSF10A. Mapatumumab (HGS-ETR1) is an experimental human monoclonal antibody for the treatment of cancer.


Specific Inquiry
  • Size:
  • Conjugation:
  • Endotoxin:
  • Purity:
  • Fc Engineering:
  • Published Data
  • Gene Expression
  • Datasheet
  • MSDS
  • Publications
  • COA

Figure 1 Mapatumumab and etoposide synergize to induce apoptosis through the mediation of NF-jB.

Figure 1 Mapatumumab and etoposide synergize to induce apoptosis through the mediation of NF-jB.

(A) Inhibition of NF-jB disrupts synergy between Mapatumumab and etoposide. HT29 cells were untreated, treated with 100 lM etoposide, 10 lM BAY 11-7082, or 100 ug/ml of Mapatumumab alone or in combination. 48 h after treatment cells were collected and cell death was assessed by acridine orange staining. Error bars represent the standard deviation of three independent experiments. Statistical significance was calculated using a Student's t test. (B) Combination treatment between Mapatumumab and Etoposide increases DNA fragmentation; this is disrupted by NFjB blockage. Cells were treated with 100 uM etoposide, 10 lM BAY 11-7082, 100 ug/ml of Mapatumumab, or 20 uM of z-VAD-FMK alone or in combination. 48 h after transfection cells were collected and stained with propidium iodide staining buffer.

Mendoza, F. J., Ishdorj, G., Hu, X., & Gibson, S. B. (2008). Death receptor-4 (DR4) expression is regulated by transcription factor NF-κB in response to etoposide treatment. Apoptosis, 13(6), 756.

Figure 2 Cleaved caspase-8 was associated with DR4 or DR5 in relation to mapatumumab or lexatumumab sensitivity.

Figure 2 Cleaved caspase-8 was associated with DR4 or DR5 in relation to mapatumumab or lexatumumab sensitivity.

Immunoprecipitation (IP) assays of mapatumumab (Mapa) or lexatumumab (Lexa) were conducted in LP1, MDN, and NCI-H929 cells. Cells (20 × 106) were incubated with or without (control) 10 μg/mL of mapatumumab (45 minutes) or lexatumumab (90 minutes) at 37°C in RPMI-1640 containing 5% FCS. For NCI-H929, cells were pretreated for 2 hours with 2.5μmol/L nutlin-3a (N) before addition of lexatumumab. The lysates were immunoprecipitated with a mix of proteins A and G (2 mg of lysate proteins were immunoprecipitated in each assay). For untreated cells, IP was conducted after addition of mapatumumab or lexatumumab to the lysates. The immunoprecipitates were analyzed for the presence of the indicated proteins by immunoblot (IB) analysis. Input, lysates of untreated or treated cells; Ct Ip< IP of control lysates (untreated cells); Ip< IP of lysates obtained from cells treated with mapatumumab or lexatumumab. *, heavy chain of mapatumumab or lexatumumab.

Surget, S., Chiron, D., Gomez-Bougie, P., Descamps, G., Ménoret, E., Bataille, R., ... & Pellat-Deceunynck, C. (2012). Cell death via DR5, but not DR4, is regulated by p53 in myeloma cells. Cancer research, canres-0487.


Specifications

  • Host Species
  • human
  • Derivation
  • human
  • Type
  • IgG1
  • Specificity
  • TNFRSF10A(tumor necrosis factor receptor (TNFR) superfamily member 10A, death receptor 4, DR4, TNF-related apoptosis-inducing ligand receptor 1, TRAILR1, TRAIL-R1, TR-1, CD261) agonistic antibody [Homo sapiens]
  • Species Reactivity
  • Human
  • Applications
  • Neut, ELISA, IF, IP, FuncS, FC, IHC
  • CAS
  • 658052-09-6
  • Generic Name
  • mapatumumab
  • MW
  • 151.89 kDa
  • Related Disease
  • Colorectal cancers

Product Property

  • Purity
  • >97%, by SDS-PAGE under reducing conditions and visualized by silver stain.

Applications

  • Application Notes
  • The TNFRSF10A antibody has been reported in applications of FC, IP.

Target

  • Alternative Names
  • mapatumumab;658052-09-6;HGS-ETR1;TRM-1;HGS-ETR1;HGS-ETR1;TNFRSF10A;tumor necrosis factor receptor superfamily, member 10a;tumor necrosis factor receptor superfamily member 10A;Apo2;CD261;DR4;TRAILR 1;TRAIL-R1;TRAIL receptor 1;death receptor 4;cytotoxic TR

Related Resources

  • Biosimilar Overview
Please refer to Mapatumumab Overview to learn more about the mechanism of action, clinical projects, and approved drugs of Mapatumumab.

Product Notes

This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:

• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production

See more details about Hi-Affi™ recombinant antibody benefits.

Downloads

Download resources about recombinant antibody development and antibody engineering to boost your research.

See other products for "Mapatumumab"

Afuco™ Anti-TNFRSF10A ADCC Recombinant Antibody (Mapatumumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant human antibody to Human TNFRSF10A. Mapatumumab (HGS-ETR1) is an experimental human monoclonal antibody for the treatment of cancer.

See other products for "TNFRSF10A"

Neutralizing Antibody

CAT Product Name Application Type
NEUT-2109CQ Mouse Anti-TNFRSF10A Recombinant Antibody (clone 32A1380) FC, IHC, Neut, WB Mouse IgG1

Rabbit Monoclonal Antibody

Single-domain Antibody

CAT Product Name Application Type
HPAB-0627-CN Camelid Anti-TNFRSF10A Recombinant Antibody (HPAB-0627-CN) ELISA VHH

ADCC Enhanced Antibody

CAT Product Name Application Type
AFC-TAB-H48 Afuco™ Anti-TNFRSF10A ADCC Recombinant Antibody (Mapatumumab), ADCC Enhanced Neut, ELISA, IF, IP, FuncS, FC ADCC enhanced antibody

Customer Reviews and Q&As

Submit a review or a question
There are currently no Customer reviews or questions for TAB-H48. Click the button above to contact us or submit your feedback about this product.
View the frequently asked questions answered by Creative Biolabs Support.

For Research Use Only. Not For Clinical Use.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Send Inquiry

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

© 2024 Creative Biolabs.
  • 0
  • 0
Cart

    Go to compare